Dimension Therapeutics
Acquired by Ultragenyx Pharmaceuticals
AAV gene therapy developer for rare diseases.
AAV gene therapy developer for rare diseases.
Investment Team
Sector
Life SciencesCategory
TherapeuticsStatus
PublicLocation
Cambridge, MAInitial Investment
2013Dimension Therapeutics was a leader in the development of AAV (adeno-associated virus) gene therapies for rare disease. Dimension Therapeutics went public in 2015 (NASDAQ: DMTX). The company has since been acquired by Ultragenyx Pharmaceuticals and is no longer a publicly traded company.